Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial. (linkinghub.elsevier.com)

Authors: Song Z … Ma Z Journal: Lancet Infectious Diseases Published: 2026-01-01 DOI: https://doi.org/10.1016/S1473-3099(25)00438-4